ATB 429

Overview

ATB-429, a novel H2S-releasing derivative of mesalamine, demonstrates significant anti-nociceptive and anti-inflammatory effects in models of irritable bowel syndrome (IBS). By releasing hydrogen sulfide (H2S), ATB-429 modulates colorectal distension-induced hypersensitivity in both healthy and postcolitic rats. It attenuates abdominal withdrawal responses and suppresses spinal c-Fos mRNA expression, indicating its potential to alleviate pain associated with gastrointestinal inflammation. Moreover, ATB-429 down-regulates colonic cyclooxygenase-2 and interleukin-1β mRNA expression, effects not observed with mesalamine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, as evidenced by reversal of ATB-429's effects with glibenclamide. These findings suggest ATB-429 could offer therapeutic benefits for managing painful intestinal disorders linked to inflammation.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Endogenous Metabolite

Product Information

• Catalog No.: HY-15026
• CAS No.: 915798-75-3
• Molecular Formula: C16H11NO3S3
• Molecular Weight: 361.46
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source